Your COPD is considered to be moderate. Your FEV1 is between 30% and 49% of the normal predicted values, and your FEV1/FVC is less than 70%. In this stage, you may experience shortness of breath ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

When you have COPD, medications can go a long way to help you breathe more easily and boost your quality of life. When you have moderate to severe disease, you and your doctor will work together ...

For this reason, two contemporaneous studies of the oral PDE-4 inhibitor roflumilast tested its added benefit in COPD patients treated with salmeterol or tiotropium. Patients with moderate to ...

HealthDay News — There is a bidirectional association between rheumatoid arthritis (RA) and chronic obstructive pulmonary ...

FDA grants breakthrough designation to tezepelumab for COPD Tezepelumab has received an FDA breakthrough therapy designation as a maintenance treatment for patients with moderate to very severe ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...

The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.